The effect of the PQ1 anti-breast cancer agent on normal tissues

Anti-Cancer Drugs

Volumn 23, Issue 9, 2012, Pages 897-905

  Ding, Ying ^a   Prasain, Keshar ^a   Nguyen, Thi D T ^a   Hua, Duy H ^a   Nguyen, Thu Annelise ^a  

^a KANSAS STATE UNIVERSITY   (United States)

Author keywords

adverse effect; anti breast cancer agent; distribution; gap junction; PQ1; toxicity

Indexed keywords

ANTINEOPLASTIC AGENT; AROMATIC HYDROCARBON RECEPTOR; CASPASE 3; CASPASE 8; CONNEXIN 43; GAP JUNCTION PROTEIN; PQ1; QUINOLINE DERIVATIVE; SURVIVIN; TAMOXIFEN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HISTOPATHOLOGY; MASS SPECTROMETRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR XENOGRAFT; WESTERN BLOTTING;

AMINOQUINOLINES; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; BREAST NEOPLASMS; CASPASE 3; CASPASE 8; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG EVALUATION, PRECLINICAL; FEMALE; GAP JUNCTIONS; INHIBITOR OF APOPTOSIS PROTEINS; MASS SPECTROMETRY; MICE; MICE, INBRED C57BL; MOLECULAR STRUCTURE; ORGAN SPECIFICITY; QUINOLINES; REPRESSOR PROTEINS; TIME FACTORS; TISSUE DISTRIBUTION;

EID: 84866003645     PISSN: 09594973     EISSN: 14735741     Source Type: Journal    
DOI: 10.1097/CAD.0b013e328354ac71     Document Type: Article

References (37)

1. Loewenstein WR. Junctional intercellular communication and the control of growth. Biochim Biophys Acta 1979; 560:1-65.
2. Vinken M, Vanhaecke T, Papeleu P, Snykers S, Henkens T, Rogiers V. Connexins and their channels in cell growth and cell death. Cell Signal 2006; 18:592-600.
3. Spanakis SG, Petridou S, Masur SK. Functional gap junctions in corneal fibroblasts and myofibroblasts. Invest Ophthalmol Vis Sci 1998; 39:1320-1328.
4. Salameh A. Life cycle of connexins: Regulation of connexin synthesis and degradation. Adv Cardiol 2006; 42:57-70.
5. Kumar NM, Gilula NB. The gap junction communication channel. Cell 1996; 84:381-388.
6. Wei CJ, Xu X, Lo CW. Connexins and cell signaling in development and disease. Annu Rev Cell Dev Biol 2004; 20:811-838.
7. Cronier L, Crespin S, Strale PO, Defamie N, Mesnil M. Gap junctions and cancer: New functions for an old story. Antioxid Redox Signal 2009; 11:323-338.
8. Pointis G, Fiorini C, Gilleron J, Carette D, Segretain D. Connexins as precocious markers and molecular targets for chemical and pharmacological agents in carcinogenesis. Curr Med Chem 2007; 14:2288-2303.
9. Laird DW, Fistouris P, Batist G, Alpert L, Huynh HT, Carystinos GD, et al. Deficiency of connexin43 gap junctions is an independent marker for breast tumors. Cancer Res 1999; 59:4104-4110.
10. Li Q, Omori Y, Nishikawa Y, Yoshioka T, Yamamoto Y, Enomoto K. Cytoplasmic accumulation of connexin32 protein enhances motility and metastatic ability of human hepatoma cells in vitro and in vivo. Int J Cancer 2007; 121:536-546.
11. Ezumi K, Yamamoto H, Murata K, Higashiyama M, Damdinsuren B, Nakamura Y, et al. Aberrant expression of connexin 26 is associated with lung metastasis of colorectal cancer. Clin Cancer Res 2008; 14:677-684.
12. Lin JH, Takano T, Cotrina ML, Arcuino G, Kang J, Liu S, et al. Connexin 43 enhances the adhesivity and mediates the invasion of malignant glioma cells. J Neurosci 2002; 22:4302-4311.
13. Kandouz M, Batist G. Gap junctions and connexins as therapeutic targets in cancer. Expert Opin Ther Targets 2010; 14:681-692.
14. Naus CC, Laird DW. Implications and challenges of connexin connections to cancer. Nat Rev Cancer 2010; 10:435-441.
15. Eghbali B, Kessler JA, Reid LM, Roy C, Spray DC. Involvement of gap junctions in tumorigenesis: Transfection of tumor cells with connexin 32 cDNA retards growth in vivo. Proc Natl Acad Sci USA 1991; 88:10701-10705.
16. Loewenstein WR, Rose B. The cell-cell channel in the control of growth. Semin Cell Biol 1992; 3:59-79.
17. Van Dillen IJ, Mulder NH, Vaalburg W, de Vries EF, Hospers GA. Influence of the bystander effect on HSV-tk/GCV gene therapy. A review. Curr Gene Ther 2002; 2:307-322.
18. Prise KM, O'Sullivan JM. Radiation-induced bystander signalling in cancer therapy. Nat Rev Cancer 2009; 9:351-360.
19. Merle P, Morvan D, Caillaud D, Demidem A. Chemotherapy-induced bystander effect in response to several chloroethylnitrosoureas: An origin independent of DNA damage? Anticancer Res 2008; 28:21-27.
20. Gakhar G, Ohira T, Shi A, Hua DH, Nguyen TA. Antitumor effect of substituted quinolines in breast cancer cells. Drug Dev Res 2008; 69:526-534.
21. Gakhar G, Hua DH, Nguyen TA. Combinational treatment of gap junctional activator and tamoxifen in breast cancer cells. Anticancer Drugs 2010; 21:77-88.
22. Shi A, Nguyen TA, Battina SK, Rana S, Takemoto DJ, Chiang PK, et al. Synthesis and anti-breast cancer activities of substituted quinolines. Bioorg Med Chem Lett 2008; 18:3364-3368.
23. Collins MK, Lopez Rivas A. The control of apoptosis in mammalian cells. Trends Biochem Sci 1993; 18:307-309.
24. Franceschi C. Cell proliferation, cell death and aging. Aging (Milano) 1989; 1:3-15.
25. Tamaki T, Naomoto Y, Kimura S, Kawashima R, Shirakawa Y, Shigemitsu K, et al. Apoptosis in normal tissues induced by anti-cancer drugs. J Int Med Res 2003; 31:6-16.
26. Elmore S. Apoptosis: A review of programmed cell death. Toxicol Pathol 2007; 35:495-516.
27. Hankinson O. The aryl hydrocarbon receptor complex. Annu Rev Pharmacol Toxicol 1995; 35:307-340.
28. Xia D, Moyana T, Xiang J. Combinational adenovirus-mediated gene therapy and dendritic cell vaccine in combating well-established tumors. Cell Res 2006; 16:241-259.
29. Wang Q, You T, Yuan D, Han X, Hong X, He B, et al. Cisplatin and oxaliplatin inhibit gap junctional communication by direct action and by reduction of connexin expression, thereby counteracting cytotoxic efficacy. J Pharmacol Exp Ther 2010; 333:903-911.
30. He B, Tong X,Wang L,Wang Q, Ye H, Liu B, et al. Tramadol and flurbiprofen depress the cytotoxicity of cisplatin via their effects on gap junctions. Clin Cancer Res 2009; 15:5803-5810.
31. Boyle RG, Travers S. Hypoxia: Targeting the tumour. Anticancer Agents Med Chem 2006; 6:281-286.
32. Kawase M, Motohashi N. New multidrug resistance reversal agents. Curr Drug Targets 2003; 4:31-43.
33. Walker PR, Smith C, Youdale T, Leblanc J, Whitfield JF, Sikorska M. Topoisomerase II-reactive chemotherapeutic drugs induce apoptosis in thymocytes. Cancer Res 1991; 51:1078-1085.
34. Story MD, Stephens LC, Tomasovic SP, Meyn RE. A role for calcium in regulating apoptosis in rat thymocytes irradiated in vitro. Int J Radiat Biol 1992; 61:243-251.
35. Ramadoss P, Marcus C, Perdew GH. Role of the aryl hydrocarbon receptor in drug metabolism. Expert Opin Drug Metab Toxicol 2005; 1:9-21.
36. Okey AB, Riddick DS, Harper PA. The Ah receptor: Mediator of the toxicity of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) and related compounds. Toxicol Lett 1994; 70:1-22.
37. Chang JT, Chang H, Chen PH, Lin SL, Lin P. Requirement of aryl hydrocarbon receptor overexpression for CYP1B1 up-regulation and cell growth in human lung adenocarcinomas. Clin Cancer Res 2007; 13:38-45.